ArticleCancers2021
Dosimetric Analysis of the Short-Ranged Particle Emitter
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Fully GMP-complient radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2026Article
- QuantitativeEJNMMI physics · 2026Article
- Cancer treatment by radioimmunotherapy: insights from a dynamical model of cancer stem cells and hypoxia effects.Scientific reports · 2026Article
- [Pharmaceutics · 2026Article
- Hydroxyquinoline-functionalised aza-crown macrocycles for lanthanide coordination.Dalton transactions (Cambridge, England : 2003) · 2026Article
- Quantitative performance of a 3D CZT and conventional SPECT/CT for Tb-161 imaging.EJNMMI physics · 2026Article
- Head-to-head comparison of [EJNMMI research · 2026Article
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Quantitative terbium-161 SPECT/CT imaging: demonstrating the feasibility of image-based dosimetry and highlighting pitfalls.EJNMMI research · 2025Article
- Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.EJNMMI radiopharmacy and chemistry · 2025Article
- Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging.EJNMMI physics · 2025Article
- Article
- First-in-human administration of [European journal of nuclear medicine and molecular imaging · 2025Article
- Article
- Review
- Review
- Quantitative calibration of Tb-161 SPECT/CT in view of personalised dosimetry assessment studies.EJNMMI physics · 2024Article
- Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.Theranostics · 2024Review
- Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection.EJNMMI physics · 2023Article
- Highlight selection of radiochemistry and radiopharmacy developments by editorial board.EJNMMI radiopharmacy and chemistry · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to analyze the required absorbed doses to detectable metastases (D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.